Nano-interventions for neurodegenerative disorders

Pharmacological Research

Volumn 62, Issue 2, 2010, Pages 166-178

  Fernandes, Clara ^a   Soni, Umangi ^a   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Blood brain barrier; Endocytosis; Nanoparticles; Toxicity; Transporters

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAVEOLIN; CLATHRIN; DENDRIMER; ETHAMBUTOL; ETOPOSIDE; FLOXURIDINE; GLYCOPROTEIN P; INDOMETACIN; INSULIN RECEPTOR; ISONIAZID; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MACROGOL 6000; MEGALIN; METHOTREXATE; MONOCARBOXYLATE TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN 2; NANOPARTICLE; NITRENDIPINE; NUCLEOSIDE TRANSPORTER; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; POLOXAMER; POLYGLACTIN; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; TRANSFERRIN RECEPTOR; DRUG;

AREA UNDER THE CURVE; ASTROCYTE; BASEMENT MEMBRANE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CELL JUNCTION; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; EFFUSION; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIA CELL; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; NANOBIOTECHNOLOGY; NANOEMULSION; NANOENCAPSULATION; NERVE CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SINGLE DRUG DOSE; TOXICITY TESTING; TRANSCYTOSIS; TUBERCULOUS MENINGITIS; ANIMAL; CHEMISTRY; CYTOLOGY; METABOLISM; NANOMEDICINE; NEURODEGENERATIVE DISEASES; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; HUMANS; NANOMEDICINE; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 77953687516     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.02.004     Document Type: Review

References (107)

1. Thomas M.B., Mansoor M.A. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv 2009, 6(3):211-225.
2. Lockman P.R., Mumper R.J., Khan M.A., Allen D.D. Nanoparticle technology for drug delivery across blood-brain barrier. Drug Dev Ind Pharm 2002, 28(1):1-12.
3. Butte A.M., Jones H.C., Abbot N.J. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J Physiol 1990, 429:47-62.
4. Smith Q.R. Advances in neurology. Alzheimer's disease 1990, vol. 51:217-222. Raven Press, New York.
5. 14C] sucrose after osmotic opening of the blood-brain barrier. Brain Res 1978, 1500(653):657.
6. Sanovich E., Bartus R.T., Fridcn P.M., Dean R.L., Le H.Q., Brightman M.W. Pathway across blood-brain barrier opened by the bradykinin agonist. RMP-7. Brain Res 1995, 705(1-2):125-135.
7. Greig N.H. Drug delivery to the brain by blood-brain barrier circumvention and drug modification. Implications of the blood-brain barrier and its manipulation 1989, 311-367. Plenum Press, New York. E.A. Neuwelt (Ed.).
8. Faraji A.H., Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009, 17:2950-2962.
9. Panayam J., Labhasetwar V. Targeting intracellular targets. Curr Drug Deliv 2004, 1:235-274.
10. Chakraborty C., Sarkar B., Hsu C.H., Wen Z.H., Lin C.S., Shieh P.C. Future prospects of nanoparticles on brain targeted drug delivery. J Neurooncol 2009, 93:285-286.
11. Nicolas W., Florence M., Sylvie C., Pierre-Olivier C. The blood-brain barrier in brain homeostasis and neurological diseases. BBA-Biomembr 2009, 1788:842-857.
12. Brightman M.W., Kadota Y. Nonpermeable and permeable vessels of the brain. NIDA Res Monogr 1992, 120:87-107.
13. Petty M.A., Lo E.H. Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 2002, 68:311-323.
14. Perlmutter L.S., Chui H.C. Microangiopathy, the vascular basement membrane and Alzheimer's disease: a review. Brain Res Bull 1990, 24:677-686.
15. Wolburg H., Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002, 38:323-337.
16. Abrahamson D.R. Recent studies on the structure and pathology of basement membranes. J Pathol 1986, 149:257-278.
17. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005, 6:931-944.
18. Janzer R.C., Raff M.C. Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 1987, 325:253-257.
19. Hori S., Ohtsuki S., Hosoya K., Nakashima E., Terasaki T. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem 2004, 89:503-513.
20. Lee S.W., Kim W.J., Choi Y.K., Song H.S., Son M.J., Gelman I.H., et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 2003, 9:900-906.
21. Wosik K., Cayrol R., Dodelet-Devillers A., Berthelet F., Bernard M., Moumdjian R., et al. Angiotensin II controls occludin function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis. J Neurosci 2007, 27:9032-9042.
22. Ulrich H., Heyo K.K. The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 2004, 36:669-701.
23. Wolfgang L., Heidrun P. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005, 76:22-76.
24. Taylor E.M. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet 2002, 41:81-92.
25. Sanjay A., Kerri L.H., Vince F., Sharad S.S., Luca C., Yogesh C.A., et al. RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci 2005, 6:61.
26. Nicole S., Libusha K., Lillian M., Mari-Wyn B., Maria T., Andrej S., et al. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy. Epilepsia 2007, 48:674-683.
27. Dean M., Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet 2005, 6:123-142.
28. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. BBA 1976, 455:152-162.
29. Bendayan R., Ronaldson P.T., Gingras D., Bendayan M. In situ localization of P-glycoprotein (P-gp; ABCB1) in human and rat brain. J Histochem Cytochem 2006, 54:1159-1167.
30. Gloria L., Karlo B., Manisha R., Alexandre P., Karolina W., Reina B. Expression of the ATP-binding cassette membrane transporter. ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. Pharm Res 2007, 24:1262-1274.
31. Junichi E., Hiroyuki K., Atsushi O., Alfred H.S., Yuichi S. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metabol Dispos 2008, 36:995-1002.
32. Palmer A.M. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiology 2009.
33. William P. Blood-brain barrier drug targeting: the future of brain drug development. Mol Intervent 2003, 3:90-105.
34. Triguero D., Buciak J.B., Yang J., Pardridge W.M. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989, 86:4761-4765.
35. Françoise H. CNS delivery via adsorptive transcytosis. AAPS 2008, 10:455-472.
36. Jones A.T., Gumbleton M., Duncan R. Understanding endocytic pathways and intracellular trafficking: a prerequisite for effective design of advanced drug delivery systems. ADDR 2003, 55:1353-1357.
37. Hervé H., Patrick C. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
38. Harush-Frenkel O., Rozentur E., Benita S., Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 2008, 2:435-443.
39. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2009.
40. Huang R., Ke W., Han L., Liu Y., Shao K., Ye L., et al. Brain-targeting mechanisms of lactoferrin-modified DNA-loaded nanoparticles. J Cereb Blood Flow Metabol 2009, 29:1914-1923.
41. Mishra V., Mahor S., Rawat A., Gupta P.N., Dubey P., Khatri K., et al. Targeted brain delivery of AZT via transferring anchored pegylated albumin nanoparticles. J Drug Target 2006, 14(1):45-53.
42. Ying X., Wen H., Lu W.-L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Rel 2010, 141(2):183-192.
43. Kratzer I., Wernig K., Panzenboeck U., Bernhart E., Reicher H., Wronski R., et al. Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Rel 2007, 117:301-311.
44. Zensi A., Begley D., Pontikis C., Legros C., Mihoreanu L., Wagner S., et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Rel 2009, 137(1):78-86.
45. Brasnjevic I., Steinbusch H.W.M., Schmitz C., Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol 2009, 87:212-251. European NanoBioPharmaceutics Research Initiative.
46. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood-brain translocation: a way to deliver drugs to the brain?. Int J Pharm 2005, 298(2):274-292.
47. Afergan E., Epstein H., Dahan R., Koroukhov N., Rohekar K., Gershon G., et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Rel 2008, 132:84-90.
48. Artzner F., Zantl R., Radler J.O. Lipid-DNA and lipid polyelectrolyte mesophases: structure and exchange kinetics. Cell Mol Biol 2000, 46:967-978.
49. da Cruz M.T., Simoes S., de Lima M.C. Improving lipoplex mediated gene transfer into C6 glioma cells and primary neurons. Exp Neurol 2004, 187:65-75.
50. Molinari A., Colone M., Calcobrini A., Stringaro A., Toccacieli L., Arancia G., et al. Cationic liposomes, loaded with m-THPC, in photodynamic therapy for malignant glioma. Toxicol In Vitro 2007, 21:230-234.
51. Obata Y., Ciofani G., Raffa V., Cuscheiri A., Mensciassi A., Shinji T., et al. Evaluation of cationic liposomes composed of an amino acid-based lipid for neuronal transfection. Nanomedicine: NBM 2009, xx:1-8. 10.1016/j.nano.2009.04.005.
52. Solans C., Izquierdo P., Nolla J., Azemar N., Garcia-Celma M. Nanoemulsions. Curr Opin Colloids Interface Sci 2005, 10:102-110.
53. Floury J., Desrumaux A., Axelos M.A.V., Legrand J. Effect of high pressure homogenisation on methylcellulose as food emulsion. J Food Eng 2003, 58:227-238.
54. Abismail B., Canselier J.P., Wilhelm A.M., Delmas H., Gourdon C. Emulsification by ultrasound: drop size distribution and stability. Ultrason Sonochem 1999, 6:75-83.
55. Bouchemal K., Briancon S., Perrier E., Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Int J Pharm 2004, 280:241-251.
56. Anton N., Gayet P., Benoit J.P., Saulnier P. Nano-emulsions and nanocapsules by the PIT method: an investigation on the role of the temperature cycling on the emulsion phase inversion. Int J Pharm 2007, 344:44-52.
57. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 2009, 379:201-209.
58. Edmond J. Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport. J Mol Neurosci 2001, 16:181-193. discussion 215-221.
59. Amiji M., Desai A., Vyas T. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 2008, 97:2745-2756.
60. Helen B. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007, 65:259-269.
61. Mora-Huertas C.E., Fessi H., Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm 2008, 10.1016/j.ijpharm.2009.10.018.
62. Lamprecht A., Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Rel 2006, 112:208-213.
63. Bansal T., Akhtar N., Jaggi M., Khar R.K., Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009, 10.1016/j.drudis.2009.07.010.
64. Battastini A.M.O. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 2009, 281:53-63.
65. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Rel 2008, 127:97-109.
66. Mishra B., Patel B., Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine: NBM 2009, xx:1-17. 10.1016/j.nano.2009.04.008.
67. Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Del Rev 2007, 59:454-477.
68. Manjunath K., Venkateshwarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 2006, 14(9):632-645.
69. Wang J.X., Sun X., Zhang Z.R. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002, 54(3):285-290.
70. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Rel 2008, 127(2):97-109.
71. Gref R., Domb A., Quellec P., Blunk T., Mueller R.H., Verbavatz J.M., et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995, 16:215-233.
72. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Rel 2001, 70:1-20.
73. Ameller T., Marsaud V., Legrand P., Gref R., Barratt G., Renoir J.-M. Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharm Res 2003, 20:1063-1070.
74. Kwon G.S. Diblock copolymer nanoparticles for drug delivery. Crit Rev Ther Drug Carr Syst 1998, 15:481-512.
75. Khuller G.K., Pandey R. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrobial Chem 2006, 57:1146-1152.
76. George J., Hasadsri L., Kreuter J., Hattori H., Iwasaki T. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 2009, 284(11):6972-6981.
77. Kabanov A.V., Batrakova E.V., Melik-Nubarov N.S., Fedoseev N.A., Dorodnich T.Y., Alakhov V.Y., et al. A new class of drug carriers: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J Control Rel 1992, 22:141-157.
78. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001, 85:1987-1997.
79. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001, 299:483-493.
80. Alakhov V., Moskaleva E., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 1996, 7:209-216.
81. Witt K.A., Gillespie T.J., Huber J.D., Egleton R.D., Davis T.P. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001, 22:2329-2343.
82. Dutta T., Jain N.K., McMillan N., Parekh H.S. Dendrimer nanocarriers as versatile vectors in gene delivery. Nanomedicine: NBM 2009, xx:1-10. 10.1016/j.nano.2009.05.005.
83. Patrice Hildgen, Dhanikula R.S., Hammady T. On the mechanism and dynamics of uptake and permeation of polyether-copolyester dendrimers across an in vitro blood-brain barrier model. J Pharmaceut Sci 2009, 98:3748-3760.
84. Dhanikula, Argaw A., Bouchard J.F., Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharmaceut 2008, 5(1):105-116.
85. Garnett M.C., Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup Med (Lond) 2006, 56(5):307-311.
86. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005, 113(7):823-839.
87. Curtis J., Greenberg M., Kester J., Phillips S., Krieger G. Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol Sci 2006, 25(4):245-260.
88. Lanone S., Boczkowski J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med 2006, 6(6):651-663.
89. Kagan V.E., Bayir H., Shvedova A.A. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine 2005, 1(4):313-316.
90. Moghimi S.M., Hunter A.C., Murray J.C. Nanomedicine: current status and future prospects. FASEB J 2005, 19(3):311-330.
91. Nanotech Rx - Medical applications of nanoscale technologies: what impact on marginalized communities? ETC group 2006; 1-63.
92. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311(5761):622-627.
93. Miller J. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Sci Technol Rev 2003, 5:1-29.
94. Chan V.S. Nanomedicine: an unresolved regulatory issue. Regul Toxicol Pharmacol 2006, 46(3):218-224.
95. Brower V. Is nanotechnology ready for primetime?. J Natl Cancer Inst 2006, 98(1):9-11.
96. Vega-Villa K.R., Takemoto J.K., Yáñez J.A., Remsberg C.M., Forrest M.L., Daviesa N.M. Clinical toxicities of nanocarrier systems. Adv Drug Del Rev 2008, 60:929-938.
97. Geze A., Putaux J.L., Choisnard L., Jehan P., Wouessidjewe D. Long-term shelf stability of amphiphilic beta-cyclodextrin nanosphere suspensions monitored by dynamic light scattering and cryo-transmission electron microscopy. J Microencapsul 2004, 21(6):607-613.
98. Liu Y., Kathan K., Saad W., Prud'homme R.K. Ostwald ripening of betacarotene nanoparticles. Phys Rev Lett 2007, 98(3):036102.
99. Kabanov A.V. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 2006, 58(15):1597-1621.
100. Hagens W.I., Oomen A.G., de Jong W.H., Cassee S F.R., Sips A.J.A.M. What do we (need to) know about the kinetic properties of nanoparticles in the body?. Regul Toxicol Pharmacol 2007, 49:217-229.
101. Kusuhara H., Sugiyamaa Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRX 2005, 2(1):73-85.
102. Löscher W., Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRX 2005, 2(1):86-98.
103. Löscher W., Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005, 76(1):22-76.
104. Sun H., Dai H., Shaik N., Elmquist W.F. Drug efflux transporters in the CNS. ADDR 2003, 55(1):83-105.
105. Christine Le Roy, Jeffrey L., Wrana Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nature Rev Molecul Cell Biol 2005, 6:112-126.
106. Doherty G.J., McMahon H.T. Mechanisms of Endocytosis. Ann Rev Biochem 2009, 78:857-902.
107. Smith M.W., Gumbleton M. Endocytosis at the blood-brain barrier: From basic understanding to drug delivery strategies. J Drug Target 2006, 14(4):191-214.